Central systolic blood pressure (SBP) may differ between individuals with similar brachial SBP, which may have implications for risk assessment. This study aimed to determine the variation and potential clinical value of central SBP between patients with similar brachial SBP. Brachial SBP was measured by sphygmomanometer and central SBP by radial tonometry in 675 people (430 men), comprising healthy individuals (n ¼ 222), patients with known or suspected coronary artery disease (n ¼ 229) and diabetes (n ¼ 224). Individuals were stratified by brachial SBP in accordance with European Society of Hypertension guidelines (optimal, normal, high-normal, grades 1, 2 and 3 hypertension). The potential clinical value of central SBP was determined from the percentage of patients re-classified into different brachial SBP groups due to the difference between brachial and aortic SBP (defined as brachial SBP-central SBP). Central SBP increased with each brachial SBP level (optimal to grade 3 hypertension; Po0.001 for all). However, large variation in brachialaortic SBP difference occurred within each brachial SBP group (range 2-33 mm Hg), resulting in sizeable overlap of central SBP between brachial SBP groups. For patients with normal brachial SBP, 96% had central SBP within the range of patients with high-normal brachial SBP, as well as 64% within the range of patients with grade 1 hypertension. We conclude that wide variation in brachial-aortic SBP difference occurs between patients with similar brachial SBP. This results in a significant overlap of central SBP scores between brachial SBP risk groups. This is likely to have treatment implications but remains to be tested.
Introduction
Current guidelines for the management of patients with hypertension focus on brachial blood pressure (BP) treatment targets. 1, 2 However, systolic BP (SBP) and, pulse pressure are amplified from the ascending aorta to the brachial artery where BP is traditionally measured. The magnitude of pressure amplification may vary and is influenced by several demographic variables including age, gender and height, 3 as well as clinical and physiological factors such as hypercholesterolemia, 4 recreational stimulants, 5 vasoactive medications, 6 mean arterial pressure, 3 heart rate, 7 exercise 8 and posture. 9 Thus, brachial cuff measures of BP may not reliably estimate central SBP and pulse pressure. Moreover, wide variance in central SBP may exist between individuals with the same, or similar, brachial SBP.
Although increased brachial BP is a strong cardiovascular risk factor, 10 several studies have identified central pulse pressure and augmentation index as independent predictors of cardiovascular morbidity and mortality. [11] [12] [13] [14] [15] [16] These data suggest that risk assessment may be improved with consideration of central BP, and this may be determined by radial tonometry using commercial equipment. 17 Despite this, there is limited information on the amount of variation in central SBP and the brachialaortic SBP difference. Data are also lacking on the potential implications of these differences in terms of classifying risk according to standard European Society of Hypertension (ESH) guidelines. Therefore, this study sought to identify (1) the variation in central SBP and the brachial-aortic SBP difference that occurs between patients falling within each ESH brachial SBP group and (2) the number of patients that may be re-classified into a different ESH brachial BP risk group based on central SBP.
Materials and methods

Subjects
Participants were outpatients attending the Princess Alexandra Hospital, Brisbane, Australia (from March 2004 to January 2007) for clinically indicated tests, or in response to advertisements for cardiovascular assessment studies. The study sample comprised 675 people (430 men) including 222 healthy individuals (that is free from known cardiovascular disease with the exception of hypertension), 224 patients with type 2 diabetes mellitus (all of which had negative exercise echocardiograms) and 229 with known or suspected coronary artery disease (confirmed by angiography or suspected from a positive dobutamine stress echocardiogram). Of the apparently healthy individuals, 105 had a negative exercise stress echocardiogram and none had a history of cardiovascular disease, treated hypertension, hypercholesterolaemia (total cholesterol X6.5 mmol l À1 ), diabetes mellitus or were taking vasoactive medications. The research was conducted according to the Declaration of Helsinki (2002). Procedures received approval from local Institutional Ethics Committees and participants provided written informed consent.
Protocol
Brachial and central BP was measured in all subjects under similar conditions. Participants were stratified according to a continuous risk gradient of brachial SBP according to the ESH guidelines for the management of hypertension (that is optimal, normal, high-normal, hypertension stages 1, 2 and 3). 1 The potential clinical significance of central SBP measurement was then assessed in terms of whether individuals were re-categorized into different brachial SBP risk groups according to central SBP and the magnitude of brachial-aortic SBP difference. Participants were not stratified based on diastolic BP (DBP) because this measure only varies marginally between the ascending aorta and the brachial artery (for example 1-3 mm Hg).
Brachial and central BP Supine brachial and central BP was measured after at least 5 min rest in a quiet temperature-controlled room. Brachial BP was obtained in duplicate by conventional mercury cuff sphygmomanometry, with SBP and DBP identified by Korotkoff sounds phases I and V, respectively. Central BP was recorded in duplicate by radial applanation tonometry and customized software (SphygmoCor 7.01; AtCor Medical, Sydney, New South Wales, Australia) which generates a central pressure waveform using a mathematical transfer function that has been validated across haemodynamic perturbations 18, 19 and shown to be highly reproducible. 20 Brachial SBP and DBP were used to calibrate the radial pressure waveform. Pulse pressure amplification was calculated as the ratio of peripheral to central pulse pressure and brachial-aortic SBP difference was defined as brachial SBP-central SBP.
Statistics
Data were presented as mean±s.d. (except where stated) and Po0.05 considered significant. Differences between patient groups were analysed by oneway analysis of variance with Bonferroni correction. Categorical variables were assessed by the w 2 -test for independence. Analysis of covariance (with the distracter variables as age, gender, heart rate and use of medication (statin, b-blocker, calcium channel blocker, angiotensin-converting enzyme inhibitor or metformin)) was used to compare differences in central SBP and the brachial-aortic SBP difference between brachial BP classification groups. Pearson product moment coefficient of correlation (r) was used to assess relationships between variables. Hierarchical multiple linear regression was performed by the enter method. Data were analysed using SPSS software version 14.0 (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
Study population characteristics are detailed in Table 1 . Both brachial and central SBP were significantly higher in the patient populations compared to the healthy subjects. On the other hand, pulse pressure (PP) amplification was significantly higher in the healthy subjects compared to the other groups. However, there was no significant difference between all groups for brachialaortic SBP difference. Furthermore, the range of brachial-aortic SBP difference was similar between groups.
Impact of brachial-aortic SBP difference on brachial SBP classification Figure 1 shows the mean ( ± 2 s.d.) central SBP and brachial-aortic SBP difference for each ESH brachial SBP risk group. Central SBP increased in a stepwise fashion (Po0.001 for all) across all brachial SBP groups ( Figure 1a) ; optimal (100 ± 8 mm Hg; range, 70-114 mm Hg), normal (113±5 mm Hg; range, 98-122 mm Hg), high-normal (122 ± 6 mm Hg; range, 104-134 mm Hg), grade 1 hypertension (133 ± 8 mm Hg; range, 112-153 mm Hg), grade 2 hypertension (154 ± 8 mm Hg, range, 139-171 mm Hg) and grade 3 hypertension (178 ± 14 mm Hg; range, 163-204 mm Hg).
The brachial-aortic SBP difference between ESH brachial SBP groups is shown in Figure 1b . Patients with optimal brachial SBP had significantly lower brachial-aortic SBP difference (10±4 mm Hg; range, 3-21 mm Hg) compared to patients with high-normal (11 ± 5 mm Hg; range, 2-28 mm Hg; Po0.05), grade 1 (13±6 mm Hg; range, 3-32 mm Hg; Po0.001), grade 2 (13±5 mm Hg; range, 4-28 mm Hg; Po0.001) and grade 3 (16±9 mm Hg; range 7-33 mm Hg; Po0.001) hypertension. Patients with normal brachial SBP had significantly lower brachial-aortic SBP difference (11±4 mm Hg; range 3-24 mm Hg) compared to patients with grades 1, 2 and 3 hypertension (Po0.001 for all). These data highlight the considerable overlap in central SBP and brachial-aortic SBP difference that may occur between ESH brachial SBP risk groups.
The percentage of overlap in central SBP between brachial SBP levels is detailed in Table 2 where it can be seen, for example, that 49% of patients with normal brachial SBP had central SBP within the entire range of patients with optimal brachial SBP. On the other hand, 64% of patients with normal brachial SBP had central SBP within the entire range of patients with grade 1 hypertension. Some degree of overlap in central SBP was evident within each ESH brachial SBP category. The greatest combined overlap occurred in patients with grade 1 hypertension (218%) and high-normal SBP (184%). The pressure waveforms in Figure 2 show a large discrepancy in brachial-aortic SBP difference and central SBP between illustrative individuals with similar brachial SBP.
Brachial-aortic SBP differences Very high brachial-aortic SBP difference (X25 mm Hg) was observed in 3.0% (n ¼ 20) of the whole study population, whereas 9.8% (n ¼ 66) had very low brachial-aortic SBP difference (p5 mm Hg). Patients with very low brachial-aortic SBP difference were significantly older (61 ± 10 vs 49 ± 15 years) and had lower brachial SBP (128 ± 16 vs 152±20 mm Hg; Po0.01 for all) compared to those with very high brachial-aortic SBP difference. However, central SBP (124 ± 16 vs 125 ± 19 mm Hg; P ¼ 0.76) and central pulse pressure (44±13 vs 48±16 mm Hg; P ¼ 0.23) did not differ significantly between groups with very low or very high brachial- Figure 1 Central systolic blood pressure (SBP; a) and brachialaortic SBP difference (b) for all study participants (n ¼ 675) classified into European Society of Hypertension blood pressure levels. The shaded area represents the range of central SBP in patients with grade 1 hypertension (HT). Data represent mean±2 s.d. and has been corrected for age, gender, heart rate and use of medications. Central SBP was significantly different between all brachial blood pressure levels (Po0.001 for all). *Po0.001 indicates significant difference from optimal, normal and high-normal groups. Figure 3 shows the distribution curves for brachial SBP, central SBP and brachial-aortic SBP difference for the study population. Both brachial and central SBP were normally distributed, but brachial-aortic SBP difference was positively skewed. Similar distribution curves for brachial-aortic SBP difference were evident across all patient groups (data not shown). The range of brachial-aortic SBP difference was similar between men (2-32 mm Hg) and women (3-33 mm Hg), but the mean values were higher in men (12.1±5.3 vs 10.3±4.8 mm Hg; Po0.001). This Correlates of brachial compared to central SBP Height was negatively correlated with both brachial (r ¼ À0.11; P ¼ 0.006) and central SBP (r ¼ À0.16; Po0.001), whereas age and heart rate were positive correlates of both SBP measures (Po0.002 for all). Three variables were identified as being differentially correlated with brachial SBP compared to central SBP. These were brachial-aortic SBP difference (r ¼ 0.28; Po0.001) and weight (r ¼ 0.10; Po0.05; only correlated with brachial SBP) and gender (0 ¼ female patient, 1 ¼ male patient; r ¼ À0.09; P ¼ 0.02; only correlated with central SBP). All correlates of brachial and central SBP mentioned above were entered into multiple regression models. The strongest determinants of brachial SBP were brachial-aortic SBP difference (b ¼ 0.35; Po0.001) and age (b ¼ 0.39; Po0.001), with the overall R 2 ¼ 26% (Po0.001). On the other hand, the strongest determinants of central SBP were age (b ¼ 0.41; Po0.001) and height (b ¼ À0.12; Po0.05), with the overall R 2 ¼ 19% (Po0.001).
Population descriptives
Discussion
The main finding of this study was that wide variation in brachial-aortic SBP difference occurs between individuals regardless of brachial SBP, gender or disease status. Furthermore, the magnitude of brachial-aortic SBP difference was similar between healthy people and those with disease, despite significant differences in brachial SBP and PP amplification. 21 and may have clinical implications, but further studies will be required to determine this.
Pressure amplification and risk
Our data raise the question as to whether brachialaortic SBP difference holds additional prognostic value beyond traditional cardiovascular risk factors. The possible importance of brachial-aortic SBP difference on end organ damage was shown in patients with essential hypertension where central SBP outweighed 24 h ambulatory BP for predicting left ventricular (LV) mass. 22 However, a larger study of relatively healthy subjects with a low rate of hypertension (20%) and LV hypertrophy (5%) showed no significant difference in the prevalence of cardiac hypertrophy when subjects were stratified into quartiles of brachial-aortic SBP difference. 23 Others have shown central pressure waveform indices to be important predictors of LV and carotid artery structure. 24, 25 We have also found an independent association between central pulse pressure and LV mass in patients with type 2 diabetes mellitus. 26 Importantly, Hashimoto et al. 27 recently reported a strong correlation between the change in pulse pressure amplification and the change in LV mass in response to anti-hypertensive therapy.
Although risk related to BP may be regarded as continuous and linear, cutoff values and treatment targets for brachial BP have been agreed upon by international experts.
1,2 These recommendations 29 Although SBP and pulse pressure are clearly elevated in these individuals (also confirmed in another larger study), 30 some have cautioned against the assumption of normality, suggesting that prospective studies are needed to determine this. 31 Indeed, the normative central BP values presented in the AngloCardiff Collaborative Trial 3 refute the proposal that central BP is normal in men with spurious systolic hypertension. Our own data tend to support this stance, as the central SBP values of the healthy subjects are similar to those of McEniery et al. 
Limitations
Although we suggest that large numbers of patients may be re-classified into different risk groups according to central SBP we are unable to say whether this reallocation may be due to metabolic or Framingham risk factors (for example blood glucose, smoking status or blood lipids) because we do not have complete information on these variables. Furthermore, we have studied a heterogeneous population that includes patients with different pathophysiological profiles and this may reduce the clinical relevance of our observations regarding the estimation of cardiovascular risk. Nonetheless, this is a 'first look' study and our findings may justify more comprehensive studies, breaking subjects down into different subsets.
Study significance
Our data suggest that if both brachial and central BP information were available to clinicians, the process of guiding therapy or quantifying the contribution of BP to total cardiovascular risk may be significantly improved in some patients. Indeed, the risk attributed to BP may be overestimated in a patient with high brachial-aortic SBP difference, such as that depicted in the upper panel of Figure 2 . Conversely, risk may be underestimated in the patient with relatively high central pressure as shown in the lower panel, or in the case of female patients who generally have lower brachial-aortic SBP difference. In each case, knowledge of central BP may change therapeutic decisions. Although speculative, these assertions are supported by a large body of evidence indicating the independent prognostic value of central haemodynamics on cardiovascular morbidity and mortality. Nevertheless, the clinical utility of tonometric central BP measurement as a management tool for physicians remains to be tested.
